Skip to content
Head to head

Omeros vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: OMER · VRTX

Updated moments ago

1-year performance, rebased to 100

OMER +45.5%VRTX +18.7%
It’s close.
OMERVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price13.21515.02
Change today-5.71%-1.08%
1-year return+60.5%+22.0%
Market cap$983.66M$130.58B
52-week range6.70 – 21.24412.27 – 568.67
Valuation
P/E (TTM)8.5233.14
P/E percentile, own 5-yr range90th99th
P/B-10.946.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.0515.32
Net profit (TTM)$-3.72M$3.88B
Revenue (TTM)$38.42M$12.95B
Provider revenue period date2026-06-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin98.9%85.5%
Operating margin-189.5%33.1%
Net margin324.9%30.7%
Free cash flow (TTM)$-68.73M$3.20B
Provider cash-flow period date2026-06-292026-09-29
Ownership & sentiment
Institutional ownership51.4%96.8%
Insider activity (12mo)35 buy / 11 sell28 buy / 22 sell
Short interest (% of float)17.7%1.9%
Analyst consensus100% buy (2)95% buy / 5% hold (21)
Analyst price target$28 (+108%)$624 (+21%)
StockVane view
StockVane Quant RatingD (91)C (68)
Company
Employees1756,400
Founded19941989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.